FOSTER PHARMACEUTICALS LIMITED --

FINANCIAL STATEMENTS FOR THE YEAR ENDED

COMPANY REGISTRATION NUMBER

31 December 2012

716242

A2HKGZAA

A34 24/09/2013
COMPANIES HOUSE

#93

FOSTER PHARMACEUTICALS LIMITED --

Balance Sheet

As at 31 December 2012

		Year ended	Year ended
		31 December 2012	31 December 2011
	NOTES	£	£
Investments in subsidiary companies		0	0
Debtors			
Amounts falling due after more than one year	1	9,579	9,579
Creditors			
Amounts falling due after more than one year	2	0	0
Total Net Assets		9,579	9,579
Capital and Reserves			
Called up share capital	3	500	500
Share premium account		0	0
Capital reserve		0	0
Revaluation reserve		9,079	9,079
Other reserves		0	0
Profit and loss account		0	0
Total shareholder's funds		9,579	9,579

For the year ending 31 December 2012 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies

Directors' responsibilities

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476, and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime

By Order of the Board

W Shepherd

Director

13 August 2013

FOSTER PHARMACEUTICALS LIMITED --

Notes to the Accounts

NOL	is to the Accounts	Year ended	Year ended
		31 December 2012	31 December 2011
		£	£
1	Debtors amounts falling due after one year		
	Amounts owed by group undertakings	9,579	9,579
2	Creditors amounts falling due after one year		
	Amounts owing to group undertakings	0	0
3	Called up share capital		
	Authorised		
	1000 Ordinary shares of £1 each	1,000	1,000
	Issued		
	500 Ordinary shares of £1 each	500 500	500 500

4 Ultimate parent undertaking and ultimate controlling party

In the opinion of the directors the company's ultimate controlling party is the ultimate parent undertaking, Franz Haniel & Cie GmbH, a company registered in Germany, by virtue of it's majority shareholding in the intermediate parent Celesio AG and it's consolidation of the Celesio AG Group results into it's own financial statements